drugset / Trial / NCT01894568

A Study Comparing Insulin Peglispro With Insulin Glargine as Basal Insulin Treatment

NCT01894568

Phase 3 Completed 388 enrolled Eli Lilly and Company
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare insulin peglispro (LY2605541) to insulin glargine in Asian insulin naïve participants who have been treated with oral anti hyperglycemia medications. Participants will receive 26 weeks of treatment.

Timeline

Start
2013-07
Primary completion
2015-04
Completion
2015-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Peglispro Protein / enzyme biologic Subcutaneous
Comparator insulin glargine Protein / enzyme biologic Subcutaneous
Background Pioglitazone Small molecule Oral